GT Biopharma Inc. (GTBP) Could Be Looking At a Massive Opportunity
“There is a revolution taking place in the practice of medicine, particularly cancer therapy, and most of that innovation is taking place in the biotech companies,” – Chris Sassouni, health care specialist and co-portfolio manager of the mid-cap growth investment team at Eagle Asset Management. Because of statements like this, the street is heavily focusing on this arena and (GTBP) could hold a key to big potential.
Ex Roche, Calico Executive Takes CSO Role At GSK
Ex- Roche and Calico vet Hal Barron is now the new CSO and chief of research at big pharma GlaxoSmithKline during a re-structuring from its new Chief Executive Officer Emma Walmsley. The new hire was on the fence since the release of a report from the Financial Times this week that stated its previous research chief Patrick Vallance took on a new endeavor with the U.K government as a science adviser. Vallance will now definitely be leaving, taking up the FT-reported role of government science adviser; he leaves March 2018.
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to October 1, 2017 to publicly disseminate information about (GTBP). We own zero shares.